26 March 2026 - UCB today announced that the CHMP of the EMA has issued a positive opinion recommending a variation to the terms of the marketing authorisation for Zilbrysq (zilucoplan), introducing a new additional device presentation via a pre-filled pen as an add-on to standard therapy for the treatment of adults living with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.

Zilucoplan pre-filled pen is a self administration device designed to automatically inject an accurate and defined dose of zilucoplan triggered by push on skin activation.

Read UCB press release